Levonorgestrel intrauterine system (LNG-IUS) with conjugated oral equine estrogen: A successful regimen for HRT in perimenopausal women

Human Reproduction

Volumn 20, Issue 9, 2005, Pages 2653-2660

  Hampton, Naomi R E ^a   Rees, M C P ^b   Lowe, D G ^c   Rauramo, I ^d   Barlow, D ^b   Guillebaud, J ^a  

^a Margaret Pyke Centre   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d Finska Lo karforeningen Duodecim   (Finland)

Author keywords

Bleeding; Endometrium; Hyperplasia; LNG IUS; Perimenopause

Indexed keywords

CONJUGATED ESTROGEN; LEVONORGESTREL;

ABDOMINAL PAIN; ACNE; ADULT; AMENORRHEA; ANKLE EDEMA; ARTHRALGIA; ARTICLE; BACKACHE; BILIARY PERITONITIS; BLOATING; BREAST CANCER; BREAST CARCINOMA; BREAST TENDERNESS; BREAST TUMOR; CLIMACTERIUM; CLINICAL TRIAL; COLPOSUSPENSION; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSMENORRHEA; DYSPEPSIA; EMOTIONAL DISORDER; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; LEUKORRHEA; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MIGRAINE; NAUSEA; OPEN STUDY; OVARY CYST; PATIENT COMPLIANCE; PATIENT MONITORING; PREMENSTRUAL SYNDROME; SIDE EFFECT; SPOTTING; SYMPTOMATOLOGY; UNITED KINGDOM; URINARY TRACT INFECTION; UTERUS BLEEDING; VAGINA BLEEDING; VASOMOTOR REFLEX; WEIGHT GAIN;

EQUIDAE;

EID: 24044442911     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/dei085     Document Type: Article

References (50)

1. Andersson K and Rybo G (1990) Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 97, 690-694.
2. Andersson K, Mattsson LA, Rybo G and Stadberg E (1992) Intrauterine release of levonorgestrel - a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 79,963-967.
3. Andersson K, Odlind V and Rybo G (1994) Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: A randomised comparative trial. Contraception 49,56-72.
4. EMEA (1997) Points to consider on hormone replacement therapy. CPMP/EWP/ 021/97. Committee for Proprietary Medicinal Products, London. November 1997.
5. Grady D, Gebretsadik T, Kerlikowske K, Ernster V and Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 85,304-313.
6. Hague S, MacKenzie IZ, Bicknell R and Rees MCP (2002) In vivo angiogenesis and progestogens. Hum Reprod 17,786-793.
7. Hahn RG (1989) Compliance considerations with estrogen replacement withdrawal bleeding and other factors. Am J Obstet Gynecol 161,1854-1858.
8. Hallberg L, Hogdahl A-M, Nilsson L and Rybo G (1966) Menstrual blood loss - a population study. Acta Obstet Gynecol 45,320-351.
9. Komulainen MH, Kroger H, Tuppurainen MT, Heikkinen AM, Alhava E, Honkanen R and Saarikoski S (1998) HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: A 5 year randomised trial. Maturitas 31,45-54.
10. Lethaby AE, Cooke I and Rees M (2001) Progesterone/progestogen releasing intrauterine systems versus either placebo or any other medication for heavy menstrual bleeding (Cochrane Review). In the Cochrane Library. Update Software, Oxford.
11. Lindgren R, Risberg B, Hammar M, Berg G and Pryse-Davies J (1992) Endometrial effects of transdermal estradiol/norethisterone acetate. Maturitas 15,71-78.
12. Luukkainen T, Allonen H, Haukkamaa M, Lahteenmaki P, Nilsson CG and Toivonen J (1986) Five years' experience with levonorgestrel IUDs. Contraception 33,139-148.
13. Magos AL, Brincat M, Studd JWW, Wardle P, Schlesinger P and O'Dowd T (1985) Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 65,496-499.
14. Mattsson LA, Cullberg G and Samsioe G (1982) Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints. Maturitas 4,95-102.
15. Mattsson LA and Sporrong T (2003) Low dose hormone replacement therapy: clinical efficacy. Minerva Ginecol 55,201-207.
16. Mattsson LA, Skouby SO, Heikkinen J, Vaheri R, Maenpaa J and Timonen U (2004) A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: Randomized comparison with a conventional-dose regimen. Climacteric 7,59-69.
17. Nilsson CG (1977) Comparative quantification of menstrual blood loss of a d-norgestrel-releasing IUD and a Nova-T-copper device. Contraception 15,379-387.
18. Pekonen F, Nyman T, Lahteenamaki P et al. (1992) Intrauterine progestin induces continuous insulin-like growth factor-binding protein-1 production in the human endometrium. J Clin Endocrinol Metab 75,660-664.
19. Perino A, Quartararo P, Catinella E et al. (1987) Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 18,137-140.
20. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF and Speroff L (2003) Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: Two-year substudy results. Fertil Steril 80,1234-1240.
21. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 889,1110-1116.
22. Pilon D, Castilloux A-M and Lelorier J (2001) Estrogen replacement therapy: Determinants of persistence with treatment. Obstet Gynecol 197,97-100.
23. Pinol A and Machin D (1988) A microcomputer software for the analysis of menstrual diaries: The menstrual diary system. Contraception 38,157-163.
24. Raudaskoski TH, Lahti EI, Kauppila A, Apaja-Sarkkinen MA and Laatikainen TJ (1995) Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol 156,1332-1334.
25. Ross AH, Boyd ME, Colgan TJ, Ferenczy A, Fugere P and Lorrain P (1993) Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: Effects on bleeding patterns and endometrial histology. Obstet Gynecol 82,773-779.
26. Rutanen EM, Salmi A and Nyman T (1997) mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod 3,749-754.
27. Rymer J and Morris EP (2000) Extracts from "clinical evidence" menopausal symptoms. BMJ 321(7275),1516-1519.
28. Salmi A, Pakarinen P, Peltola AM and Rutanen EM (1998) The effect of intrauterine levonorgestrel use on the expression of c-JUN, oestrogen receptors, progesterone receptors and Ki-67 in human endometrium. Mol Hum Reprod 4,1110-1115.
29. Scarselli G, Tantini C, Colafranceschi M et al. (1988) Levo-norgestrel-nova T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 9,284-286.
30. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG and Luukkainen T (1986) Endometrial morphology during long-term use of levonorgestrel releasing intrauterine devices. Int J Gynecol Path 5,235-241.
31. Sivin I, El-Maghoub S, McCarthy T, Mishell DR, Shoupe D, Alvarez F, Brache V, Jimenez E, Diaz J and Faundes A (1990) Long-term contraception with the loevonorgestrel 20 μg/day (LNG 20) and the copper T 380 Ag intra-uterine devices: A five year randomised study. Contraception 42,361-378.
32. Staland B (1981) Continuous treatment with natural oestrogens and progestogens. A method to avoid endometrial stimulation. Maturitas 3,145-156.
33. Sturdee DW, Ulrick LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC and Bragg AJ (2000) The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynaecol 107,1392-1400.
34. Suhonen SP, Holmstrom T, Allonen H and Lahteenmaki P (1995a) Intrauterine and subdermal progestin administration in postmenopausal hormone therapy. Fertil Steril 63,336-342.
35. Suhonen SP, Allonen H and Lahteenmaki P (1995b) Sustained release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 172,562-567.
36. Suhonen S, Haukkamaa M, Holmstrom T, Lahteenmaki P and Rutanen EM (1996) Endometrial response to hormone replacement therapy as assessed by expression of insulin-like growth factor-binding protein-1 in the endometrium. Fertil Steril 65,776-782.
37. Suhonen SP, Holmstrom T and Lahteenmaki P (1997) Three year follow-up of the use of a levonorgestrel-releasing system in hormone replacement therapy. Acta Obstet Gynecol Scand 76,145-150.
38. Suvanto-Luukkonen E and Kauppila A (1999) The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five year experience. Fertil Steril 72,161-163.
39. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Kauppila A and Rutanen EM (1995) Insulin-like growth factor-binding protein-1: A biochemical marker of endometrial response to progestin during hormone replacement therapy. Maturitas 22,255-262.
40. Suvanto-Luukkonen E, Sundstrom H, Penttinen J, Laara E, Pramila S and Kauppila A (1997) Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas 26,211-217.
41. Torgerson DJ and Bell-Syer SEM (2001) Hormone replacement therapy and prevention of nonvertebral fractures. A meta-analysis of randomized trials. J Am Med Assoc 285,2891-2897.
42. Van Bogaert LJ (1988) Clinicopathologic findings in endometrial polyps. Obstet Gynecol 5,771-773.
43. Varila E, Wahlstrom T and Rauramo I (2001) A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 76,969-973.
44. Weiderpass E, Adami H-O, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N and Persson I (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91,1131-1137.
45. Weinstein L, Belwtra C and Gallagher JC (1990) Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol 162,1534-1542.
46. Wells M, Sturdee DW, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, Vessey MP and Bragg AJ (2002) Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: Follow-up study. Br Med J 325(7358),231-232.
47. Williams SR, Frenchek B, Speroff T and Speroff L (1990) A study of combined continuous ethinyloestradiol and norethindrone acetate for postmenopausal hormone replacement. Am J Obstet Gynecol 162,438-446.
48. Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J Am Med Assoc 275,370-375.
49. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288,321-333.
50. Zhu P, Luo HZ, Xu RH, Cheng J, Wu SC, Chen JH, Wu MZ and Wang XP (1989) The effect of intrauterine devices, the stainless steel ring, the Copper T 220 and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium - a comparative study of three IUDs. A morphometric study of 96 cases. Contraception 40, 425-438.